At a glance: EMEA review of COX-2 inhibitors

The anti-inflammatories used in the treatment of arthritis? The very ones, generally used by sufferers of osteoarthritis and rheumatoid arthritis. The European Medicines Agency (EMEA) has been asked by the European Commission to review COX-2 inhibitor medicines in the wake of the worldwide withdrawal on 30 September of Merck’s Vioxx, the brand name for rofecoxib.

Sign in to continue

Sign in

Sign in

Trouble signing in?

Reset password: Click here

US and Asia
subscriptions@prweek.com
+001 (800) 558-1708

UK & Europe
support@prweek.com
+44 (0)20 8267 8121

Register

Don't have an account? Complete easy registration and receive:

  • Limited Article Views (Excludes Subscriber Only Content)
  • Select Newsletters (Excludes Subscriber Only Bulletins)

Register Now

Register

FREE

  • Limited free articles a month
  • Limited number of free email bulletins

Register Now

Subscribe

To receive full access to PRWeek's content subscribe today and receive:

  • Unlimited access to PRWeek content
  • Daily Breakfast Briefing
  • Breaking News Alerts
  • Weekly Online Edition
  • Agency Business Report
  • Weekender Edition
  • PRWeek Magazine
  • Full Archive Access

Subscribe Options

Start your free trial 

Enjoy these subscriber-exclusive benefits:

  • Unrestricted individual access to prweek.com
  • Breaking news and industry updates via PRWeek Daily News bulletin
  • Exclusive access to Power Book and Top 150 UK Agency Business Report

Join today

Need to activate your subscription?

Domain/Group Subscriptions
Click here >>

Individual Subscriptions
Click here >>

Need to activate your Subscription

Company Wide Subscriptions
Click here >>

 UK Individual Subscribers
Click here >>